alexa Predictive Role Of Rheumatoid Factor And Anti-cyclic Citrullinated Peptide Regarding The Response To Antitumor Necrosis Factor Therapy In Rheumatoid Arthritis
ISSN: 1745-7580

Immunome Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th Molecular Immunology and Immunogenetics Congress
March 20-21, 2017 Rome, Italy

Gavrila B I, Claudia Ciofu, Carina Mihai, Bojinca M, Gabriela Udrea, Stoica V, Ciotaru D, Mihaela Surcel, Adrina Munteanu, Ursaciuc C and Eugenia Panaitescu
Carol Davila University of Medicine and Pharmacy, Romania
Victor Babes National Institute, Romania
ScientificTracks Abstracts: J Immunome Res
DOI: 10.4172/1745-7580.C1.011
Abstract
Background: The introduction of biologic therapy has revolutionized the treatment of rheumatoid arthritis (RA). Despite these advances, 20-40% of the patients are declared non-responders to at least one of the therapies. Objectives: Evaluating the predictive role for the response to anti-tumor necrosis factor therapy of rheumatoid factor (RF) isotypes IgM, IgA, anti-cyclic citrullinated peptide (anti-CCP) and the evolution of serum levels of these biomarkers under biologic treatment. We have also assessed the status of this biomarkers and the response to treatment. Methods: Prospective and observational study including 64 patients was followed for 12 months with active RA, uncontrolled by conventional synthetic DMARDs or declared non-responders to one of the biologic DMARDs. Results: Lower baseline titres of RF type IgM (51.36±95.359 U/ml, p=0.01629), IgA (22.45±61.256 U/ml, p=0.03336) and anti-CCP (60.82±26.331 ng/ml, p=0.00011) had predictive value for achieving a good EULAR response at 6 months. Grouping patients in 2 categories (responders/non-responders), we identified significant differences between groups only for anti-CCP and response at 6 months (responders 96.04±50.355 ng/ml, non-responders 146.16±41.68 ng/ml, p=0.02834). For the EULAR response at 12 months, lower baseline titres for RF type IgM (92.93±120.22 U/ml, p=0.01032) and IgA (49.96±98.08 U/ml, p=0.00247) had predictive value for achieving a good response at 12 months. We didn’t obtain other information grouping patients in 2 categories. Monitoring the evolution of serum levels, we noticed reduction in all three biomarkers tested, statistically significant at 6 and/or 12 months from baseline. Regarding the status (positive/negative) pretreatment and the response to anti-TNF agents, we noticed significant differences regarding status for RF IgA isotype and response to treatment at 12 months (p=0.004). Conclusion: It can be concluded that, beside their diagnostic role, these biomarkers can be used for other purposes in RA.
Biography

Gavrilă B I did his PhD in Internal Medicine, and now he is an Assistant Professor at Dr. I Cantacuzino Clincal Hospital, Department of Internal Medicine and Rheumatology in Bucharest.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords